| Dimensions and components | Categories | DHC (N = 15) | CHC (N = 5) | ZH/DH (N = 7) |
| n (%) | n (%) | n (%) | ||
| Structures: human resources | Minimum trained qualified human resources in NCDs | 2 (13.3) | 1 (20.0) | 1 (14.3) |
| Structures: materials | High blood pressure treatment protocol | 3 (20.0) | 2 (40.0) | 6 (85.7) |
|
| Material for IEC | 1 (6.7) | 0 (0.0) | 1 (14.2) |
|
| Functional Kit (Ribbon, bathroom scale, measuring rod) | 13 (86.7) | 4 (80.0) | 7 (100.0) |
|
| Functional Stethoscope | 14 (93.3) | 5 (100.0) | 7 (100.0) |
|
| Functional Blood Pressure Monitor | 12 (80.0) | 5 (100.0) | 7 (100.0) |
| Structures: community actions | Awareness of the population | 0 (00.0) | 0 (00.0) | 1 (14.3) |
|
| Patient Support Group | 0 (00.0) | 0 (00.0) | 0 (00.0) |
| Structures: complementary exams |
|
|
|
|
|
| Blood glucose | -- | 4 (80.0) | 7 (100.0) |
|
| Creatininemia | -- | 3 (60.0) | 7 (100.0) |
|
| Cholesterolemia | -- | 2 (40.0) | 6 (85.7) |
|
| EKG | -- | -- | 4 (57.1) |
|
| Proteinuria/24h | -- | -- | 4 (57.1) |
|
| Eye examen | -- | -- | 5 (71.4) |
| Structures: essential drugs | Thiazide (Hydrochlorothiazide) | 13 (86.7) | 4 (80.0) | 5 (71.4) |
|
| Central antihypertensor (Methyldopa) | 15 (100.0) | 5 (100.0) | 7 (100.0) |
|
| Conversion enzyme inhibitors (Captopril) | -- | 2 (40.0) | 2 (28.6) |
|
| Calcic channel blockers (Long acting Nifedipine, Amlodipine) | -- | 5 (100.0) | 6 (85.7) |
| Clinical process | Systematic blood pressure measurement | 14 (93.3) | 3 (60.0) | 6 (85.7) |
|
| Systematic weight measurement | 12 (80.0) | 3 (60.0) | 5 (71.4) |
|
| Systematic height recording | 2 (13.3) | 0 (14.3) | 5 (71.4) |
|
| At least one follow-up visit per patient* | 4 (26.3) | 2 (40.0) | 0 (0.0) |
|
| At least two follow-up visits per patient* | 0.0 | 0.0 | 0 (0.0) |